-
RBC Capital Markets Is Lowering PHARMACYCLICS INC (PCYC) 4Q13 Estimate To -0.06 From 0.28
5/2/2013
|
-
RBC Capital Markets Is Cutting PHARMACYCLICS INC (PCYC) 3Q13 Estimate To -0.09 From 0.24
5/2/2013
|
-
RBC Capital Markets Is Lowering PHARMACYCLICS INC (PCYC) 2Q13 Estimate To -0.22 From 0.14
5/2/2013
|
-
RBC Capital Markets Is Cutting PHARMACYCLICS INC (PCYC) FY13 Estimate To -1.11 From 0.24
5/2/2013
|
-
RBC Capital Markets Is Increasing PHARMACYCLICS INC (PCYC) FY13 Rev. Estimate To 137.6 M From 137.0 M
5/2/2013
|
-
Pharmacyclics Posts Q1 Loss Per Share Of $0.73 Vs. Loss $0.19 Year Ago
5/1/2013
|
|
|
-
Pharmacyclics Completes Enrollment Of First Phase III Ibrutinib CLL Study - RESONATE
4/18/2013
|
-
Pharmacyclics Announces Enrollment Of 5th Patient In Frontline Phase III CLL Study
4/11/2013
|
|
|